Jazz Pharmaceuticals plc
NASDAQ: JAZZ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Renee D. Gala
- Employees
- 2,890
- Headquarters
- Dublin, Ireland
- IPO year
- 2007
- Market cap
- $14.9B
- Website
- https://www.jazzpharma.com
Loading JAZZ…
Loading profile data…Frequently asked questions about JAZZ
What does Jazz Pharmaceuticals plc (JAZZ) do?
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Drave...
Where does JAZZ trade?
Jazz Pharmaceuticals plc (JAZZ) trades on the NASDAQ.
What sector is JAZZ in?
Jazz Pharmaceuticals plc (JAZZ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Jazz Pharmaceuticals plc?
Renee D. Gala is the chief executive officer of Jazz Pharmaceuticals plc (JAZZ).
Where is Jazz Pharmaceuticals plc headquartered?
Jazz Pharmaceuticals plc is headquartered in Ireland.
Does JAZZ pay a dividend?
Jazz Pharmaceuticals plc (JAZZ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did JAZZ go public?
Jazz Pharmaceuticals plc (JAZZ) completed its initial public offering in 2007.